Age ≥ 18 years

Documented diagnosis of multiple myeloma according to the IMWG diagnostic criteria

Documented evidence of measurable disease:

1. Serum M-protein level ≥ 1 g/dL
2. Urine M-protein level ≥ 200 mg/24h
3. Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio

Documented evidence of PD by IMWG 2016 criteria based on investigator's determination during or after the most recent line of therapy. Participants with only 1 prior line of therapy must have progressed within 47 months of a stem cell transplant, or if not transplanted, then within 42 months of starting initial therapy

Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody. Participant must have undergone at least 2 complete cycles of treatment for each line of therapy, unless PD was the best response to the line of therapy

Eligible to receive at least one of the standard regimens (DKd, PVd, DPd, or Kd) as determined by the Investigator.

ECOG performance status score of 0 to 1

Adequate hematology and chemistry laboratory values:

1. Haemoglobin ≥ 8.0 g/dL
2. Absolute neutrophil count ≥ 1 × 10^9/L (1000 per mm3)
3. Platelet count ≥ 75 × 10^9/L (75000 per mm3) in participants with < 50% of bone marrow nucleated cells are plasma cells or ≥ 50 × 10^9/L (50000 per mm3) in participants with ≥ 50% of bone marrow nucleated cells are plasma cells
4. Absolute lymphocyte count ≥ 300/µL (0.3 × 109/L)
5. Total bilirubin ≤ 1.5 × ULN in the absence of Gilbert's syndrome or ≤ 3 × ULN if the participant has Gilbert's syndrome. AST and ALT≤ 3.0 × ULN. CrCl by Cockcroft and Gault method ≥ 30 mL/minute